CORAL GABLES, Fla., November 4, 2025 — Relmada Therapeutics, Inc. (Nasdaq: RLMD), a clinical-stage biopharmaceutical company focused on developing novel therapies for central nervous system (CNS) and oncology-related disorders, announced the pricing of its $100 million underwritten public offering of common stock and pre-funded warrants. The transaction includes the issuance of approximately 40.1 million shares of common stock and 5.3 million pre-funded warrants at an offering price of $2.20 per share or warrant, with closing expected on November 5, 2025. The proceeds will fuel Relmada’s next phase of drug development, strengthen its financial flexibility, and position the company for long-term growth in neuroscience and oncology therapeutics.
Science Significance
Relmada’s R&D pipeline centers on next-generation small molecules and biologics designed to address serious neuropsychiatric and cancer indications. The company’s lead programs include NDV-01, a novel NMDA receptor modulator for treatment-resistant depression and neuropathic pain, and Sepranolone, an investigational agent targeting stress- and hormone-related CNS dysfunctions. These assets represent a scientifically diverse portfolio built on neurotransmitter modulation, receptor selectivity, and precision pharmacology. In oncology, Relmada is advancing preclinical candidates focused on epigenetic modulation and tumor immune microenvironment regulation. The $100 million funding provides crucial support for ongoing Phase 2 trials, new IND-enabling studies, and translational biomarker discovery. This scientific continuity ensures that Relmada can sustain the pace of innovation needed to bridge neuroscience and oncology therapeutics within a unified clinical platform.
Regulatory Significance
The offering was conducted under an effective shelf registration (Form S-3) previously approved by the U.S. Securities and Exchange Commission (SEC). This approach demonstrates Relmada’s adherence to U.S. securities law, disclosure accuracy, and financial governance while enabling efficient access to public capital markets. On the clinical side, proceeds from the financing will support Good Clinical Practice (GCP) operations and regulatory engagement with the U.S. Food and Drug Administration (FDA) and other global authorities. The company’s integrated regulatory strategy—spanning data integrity, safety reporting, and statistical transparency—positions it for accelerated FDA submissions and endpoint validation. By maintaining strong compliance standards and open communication with regulators, Relmada reinforces its credibility as a science-first, governance-driven organization advancing complex CNS therapies.
Business Significance
Advertisement
The $100 million raise significantly enhances Relmada’s liquidity, extending its operational runway and enabling broader strategic execution. The financing was led by top-tier institutional investors, including OrbiMed, Janus Henderson Investors, Columbia Threadneedle Investments, and Ferring Ventures SA, underscoring institutional confidence in Relmada’s pipeline. The joint book-running managers—Jefferies, Leerink Partners, and Mizuho—structured the offering to optimize balance-sheet strength without excessive dilution. These proceeds will fund clinical development, R&D innovation, manufacturing scale-up, and potential licensing or co-development agreements. The transaction also signals continued investor optimism in late-stage neuroscience and oncology programs, areas with growing unmet need and commercial potential exceeding $30 billion annually. In an era when biotech funding is increasingly selective, Relmada’s successful offering highlights capital discipline, scientific credibility, and investor trust in its growth trajectory.
Patients’ Significance
For patients, this financing is not just a financial milestone—it represents sustained progress toward new treatment options for complex, underserved disorders. Conditions like major depressive disorder, neuropathic pain, and cancer-associated distress remain difficult to treat with existing therapies, often due to limited efficacy or intolerable side effects. Relmada’s approach—using targeted receptor modulation and mechanistic innovation—has the potential to deliver faster-acting, more tolerable, and personalized therapeutics. Continued funding ensures that pivotal studies remain uninterrupted and that clinical endpoints meaningful to patients—such as functional recovery, pain reduction, and quality-of-life improvement—remain central to program design. Ultimately, this capital raise supports translational research that could reshape standards of care in mental health and oncology.
Policy Significance
Relmada’s successful financing reflects a broader policy and economic environment supporting biotech innovation and investment. Regulatory and capital-market frameworks in the United States continue to promote clinical-stage financing, investor transparency, and responsible corporate governance. This transaction also illustrates how public-market participation complements venture and private equity capital in sustaining biomedical innovation pipelines. It reinforces the success of the SEC’s shelf-registration model, which provides biotech firms with rapid, compliant access to liquidity. Furthermore, Relmada’s investor alignment supports policy objectives related to CNS-drug innovation, a therapeutic area historically underfunded but now recognized by agencies such as NIH and FDA as critical to national mental-health priorities.
he $100 million underwritten offering solidifies Relmada Therapeutics’ transformation from an emerging biotech into a financially fortified, clinically advanced innovator. With strengthened capital resources, regulatory momentum, and a science-driven strategy, the company is positioned to accelerate its CNS and oncology programs toward late-stage milestones and potential commercialization. As investors continue to favor companies that combine robust governance with meaningful innovation, Relmada stands as a model for how disciplined biotech financing can fuel the next generation of therapies addressing critical neurological and oncologic unmet needs. The transaction represents not just an infusion of capital but a reaffirmation of confidence in Relmada’s mission to advance science that transforms lives.
Source: Relmada Therapeutics, Inc. press release
